TFS HealthScience Standardizes on Veeva Vault Clinical Operations Suite to Accelerate Clinical Development
Veeva Systems (NYSE: VEEV) today announced that TFS HealthScience selected Veeva Vault Clinical Operations Suite for end-to-end study management on a single cloud platform. The global CRO is taking action to further modernize study operations, adopting the entire suite for greater efficiency and speed in trials. Now TFS HealthScience will offer its biopharma customers industry-leading technologies and services to run more cost-efficient and compliant studies.
"Veeva Vault Clinical Operations Suite gives us a foundation for further growth as we expand our service offerings globally," said Dr. Bassem Saleh, CEO, TFS HealthScience. "Bringing together study operations streamlines processes, enabling us to maximize value for sponsors and accelerate the delivery of treatments to patients."
TFS HealthScience provides customers with strategically tailored solutions focused on driving excellence and innovation to reduce complexity in trials. Building on its success with Veeva Vault eTMF to maintain inspection readiness, the company will use Veeva Vault Study Startup to get studies up and running quickly, Veeva Vault CTMS to keep studies on track, and Veeva Vault Payments to simplify payments to global partner sites. With a connected, agile clinical landscape, TFS HealthScience will centralize governance and study oversight to share insights with sponsors easily.
"With Veeva Vault, we now have complete visibility into study progress and deviations to make better, more informed decisions and ensure studies meet their objectives," said Young Shon, CIO, TFS HealthScience. "Our partnership with Veeva is instrumental to TFS's digital transformation program and our strategic push towards paperless and patient-centric approaches."
"TFS HealthScience is transforming clinical operations to work more efficiently and better serve sponsors," said Pinar Benet, senior director strategy, Vault Clinical Operations at Veeva Systems. "We're excited to continue this journey together towards unified and connected trials to accelerate clinical research."
Vault Clinical Operations Suite enables sponsors and CROs to seamlessly share information and documents across CTMS, eTMF, study start-up, and payments for better collaboration and increased efficiency throughout the study lifecycle.
The Veeva Unified Clinical Operations Survey: Annual CRO Report shows that CROs like TFS HealthScience are moving to streamline trial execution by embracing new digital strategies and technologies that eliminate data silos and manual processes. Learn how CROs are modernizing clinical operations to speed trials in the full report, available online at veeva.com/CROReport.
About TFS HealthScience
TFS HealthScience is a global contract research organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 700 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through three strong business models: clinical development services (CDS), which provides full-service support at all stages of the clinical development process, strategic resourcing solutions (SRS), which offers expert insourcing and targeted recruitment services, and functional services (FSP), to provide customers with strategic workforce management solutions. For more information, visit www.tfscro.com
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended October 31, 2020. This is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
+48 787 913 074
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs14.4.2021 03:00:00 EEST | Press release
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies with enhanced biological function for an undisclosed oncology target. Under the terms of the agreement RubrYc and Zai Labs will collaborate to identify product candidates using RubrYc’s Discovery Engine, which leverages machine learning and structural data to identify antibodies that bind to subdominant epitopes and exhibit differentiated activity. Upon exercise of the license option Zai Labs would have exclusive global rights to develop and commercialize product(s) of the Research Collaboration. RubrYc Therapeutics, Inc. will receive an upfront payment and is eligible to receive future research, development and commercialization milestones on a per candidate basi
CGTN: A City on the Rebound: How Hong Kong Can Move Forward13.4.2021 20:57:00 EEST | Press release
The past two years have been tough on the world, not just due to the pandemic but also the geopolitical volatility that has roiled many countries and regions. In East Asia, the financial hub of Hong Kong has experienced its fair share of difficulties, but as life slowly returns to normal, problems that have plagued the city for decades remain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413006039/en/ (Photo: Business Wire) The city's brief history is well-documented – its humble industrialization in the 1970s coupled with the entrepreneurial spirit of its residents saw it become a bastion of wealth at a time when that part of the world was still economically stagnant. Coupled with a liberalized financial system and generous policies, the city catapulted itself toward the top, competing with mega-cities such as London and New York City. For all its glitz and glamour, Hong Kong contained contradictions that boiled over i
Tigo Intellectual Property Infringement Lawsuit against APS Continues to Grow13.4.2021 20:53:00 EEST | Press release
Tigo Energy, Inc., the solar industry worldwide leader in Flex-MLPE (Module Level Power Electronics), has filed a new lawsuit against Altenergy Power Systems (“APsystems”), in addition to its current ongoing case. The complaint includes four new patent infringement claims, as well as an additional claim from a patent asserted in the previously-filed lawsuit. The complaint was filed in the United States District Court for the Northern District of California. The total number of Patents-in-Suit in both cases now stands at six. The complaint includes all APsystems legal entities in the US as well as in China. The new complaint alleges that APsystems’ Sunspec-compliant products infringe the following U.S. patents: 8,653,689, 9,584,021, 9,966,848, 10,333,405, and 8,933,321. The complaint centers around various systems and methods used in the PV module rapid shutdown unit. Tigo’s industry leading solar equipment provides optimized, monitored and safe solar to protect this critical infrastruc
Maxon Announces Cinema 4D S2413.4.2021 19:05:00 EEST | Press release
Maxon, the developers of professional software solutions for motion designers and visual effects artists, today announced Cinema 4D Subscription Release 24 (S24). The latest subscription-only release of Maxon’s 3D application allows users to easily browse and obtain models, materials and other assets, and to intuitively place them within the scene. The release also includes key workflow enhancements and a sneak peek at continued progress on the Scene Nodes and Scene Manager interfaces to the new core. Cinema 4D S24 is immediately available for subscription customers. For perpetual license holders of Cinema 4D a release is scheduled later this year that will incorporate the features of S24, as well as future enhancements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005918/en/ Maxon Cinema 4D S24 features placement tools, a new asset browser, animation workflow enhancements, and continued development on powerful nodes
Maxon Announces Redshift for macOS Including Native Support for M1-Powered Macs13.4.2021 19:05:00 EEST | Press release
Today, Maxon announced the immediate availability of Redshift for macOS including support for M1-powered Macs as well as Apple’s Metal Graphics API. Redshift, the award-winning, production-ready renderer, offers a rich feature set including ray switches, flexible shading networks, motion blur, AOVs, deep output, layered EXR and much more. Unlike other GPU renderers, Redshift is a biased renderer that enables artists to adjust the quality of individual techniques in order to get the best performance/quality balance for production. As a Universal solution, Redshift is optimized for high-end performance across both M1- and Intel-powered Macs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005903/en/ Redshift for macOS signifies a milestone, bringing cutting-edge cinematic rendering to Mac artists. (Graphic: Business Wire) Redshift for macOS signifies a milestone, bringing cutting-edge cinematic rendering to Mac artists. A
Golden Euro -pelaaja voitti ennätyksellisen 3 miljoonan euron jättipotin13.4.2021 18:29:00 EEST | Tiedote
samppanja on virrannut ja juhlat ovat olleet käynnissä Golden Euro -kasinolla sen jälkeen, kun onnekas pelaaja voitti jackpotin ja sai jättimäisen 3 746 291 € voiton. Pelaajan voitto irtosi Realtime Gamingin valtavan suositusta Aztec Millions -kolikkopelistä, ja se on suurin koskaan progressiivisesta jättipottipelistä ja Golden Euro -kasinolta voitettu voitto. Peli-istuntonsa alussa 49-vuotias pelaaja teki 27 € luottokorttitalletuksen ja lunasti Golden Euron rakastetun 50 % talletusbonuksen, joten hänellä oli pelikassassaan 54 €. Voiton toi pieni 5 € yksittäispanos, jonka hän asetti älypuhelimellaan. Kun rullat pysähtyivät ja jättipotti käynnistyi, panos teki pelaajasta välittömästi monimiljonäärin. Golden Euro -kasinon Adrian Berger sanoi: ”Olemme niin iloisia, että yksi pelaajistamme on saanut suurimman jättipottivoiton koskaan Realtime Gamingin Aztec Millions -pelistä. Puhuin pelaajan kanssa pian hänen voittonsa vahvistamisen jälkeen, ja hän oli todella innoissaan, vaikkei hän vielä
Agthia Embarks on Transformational Journey with its Strategy to Become an F&B Leader by 202513.4.2021 18:06:00 EEST | Press release
Agthia Group PJSC revealed its long-term strategy to become an F&B leader in the Middle East, North Africa and Pakistan (MENAP) region and beyond by 2025. The strategy is built on three strategic pillars (growth, efficiency and capability) and is designed to extend the Group’s market leadership, provide significant value for all stakeholders and continue to drive profitability growth with a consumer-centric approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005841/en/ Khalifa Sultan Al Suwaidi - Chairman - Agthia Group (Photo: AETOSWire) The Abu Dhabi-based organisation is engaged in manufacturing, distribution and marketing of a wide range of F&B products, including popular regional brands such as Al Ain (water), Al Foah (dates), Al Faysal Bakery & Sweets (bakery) and Grand Mills (flour and bakery) among others. Khalifa Sultan Al Suwaidi, Chairman, Agthia Group, said: “The strategy will unleash the full potentia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom